Aerska

Jack O’Meara is the CEO and co-founder of Aerska, a next-generation biotech company reshaping how advanced therapies reach patients. A biomedical engineer by training, Jack’s career bridges company creation, healthtech, and biopharma. He helped shepherd one of the first blockbuster gene therapies through FDA approval and launch — experience that fuels his mission to bring new science to market faster and more accessibly.

Stuart Milstein is the Co-Founder and CEO of Aerska, a biotechnology company developing next-generation therapies for respiratory disease. He brings deep scientific expertise in molecular biology and translational research, with experience spanning early-stage drug discovery to clinical development. At Aerska, Stuart leads the company’s vision to reimagine how respiratory conditions are treated — transforming complex science into tangible, life-changing medicines.

Dave’s background spans biotech entrepreneurship, start-up growth, and investing. Prior to founding Aerska, Dave worked with Pathway Bioventures, contributing to investments in RNA and gene editing companies, and served as commercial lead for an RCSI University project focused on developing RNA therapeutics. Previously, he held roles at ONK Therapeutics, supporting their growth from seed through Series A, and at AveXis (now Novartis Gene Therapies), where he worked on the global launch of Zolgensma for SMA. Dave began his career co-founding and leading business development at Structured Immunity, a spin-out company that applied structural and computational biology to improve drug discovery.